Jump to content

giants

Senior Member
  • Posts

    275
  • Joined

  • Last visited

Posts posted by giants

  1. the cure for hair loss should come pretty soon and as i perdicted on a post awhile back this new study will cause hiar follicals to build up an immunity with no sexual side-effects.

     

    read on...

     

     

    SAN DIEGO "??? AndroScience Corporation, a privately held biotech company, has successfully filed an IND with the FDA for a new topical acne medication and will proceed with human clinical trials in the first quarter of 2007.

     

    The new compound called ASC-J9 is a "novel anti-androgen that enhances androgen receptor degradation." The product will be compounded into a topical cream that will be tested as an acne treatment.

     

     

     

    AndroScience recently discovered and patented their family of compounds which are derived from natural products. They claim these compounds selectively enhance androgen receptor degradation and do not affect endogenous androgens, testosterone or dihydrotestosterone (DHT).

     

    This is a very interesting and exciting potential treatment for Androgenetic Alopecia.

     

    Conventional hair loss treatments like Propecia work by reducing the bodies' production of DHT, the hormone that causes male pattern baldness (MPB). The problem is that a reduction of DHT in the body can lead to unwanted side effects.

     

    One way around this is to attack the problem in a different way and to block the androgen receptor sites where the DHT attaches to the cells, thus preventing the DHT from harming the hair follicle.

     

    What this new compound appears to do is to go one step further and actually damage or degrade the androgen receptors. Since it's a topical product it should allow a hair follicle to essentially become immune to the effects of DHT while not causing any other side effects in the body.

     

    If this does work as intended it could be a huge breakthrough in hair loss treatments.

     

    AndroScience won the Third Place Award (out of >900 posters) for its presentation entitled "Androgen Receptor Degradation (ARD) Enhancer: A Potential Application for Topical Treatment of Acne Vulgaris" at the Annual Meeting of American Academy of Dermatology in March of 2006; and in July 2006, AndroScience was awarded a Phase II SBIR grant ($800,000) from the NIH to develop ASC-J9 for acne treatment.

     

    AndroScience also has drug candidates in preclinical testing for the treatment of alopecia, prostate cancer, benign prostate hyperplasia (BPH) and other androgen related disorders. AndroScience intends to build up corporate value by developing its proprietary compounds through preclinical and clinical development to registration and commercialization.

     

    We will bring you more information about this potentially groundbreaking development soon.

  2. Heres the deal. This site may be slightly corrupted, so what? Bill, fllica ect... are smart people with a vast knowledge of hair loss. They know what works what doesn't and how to approach hair loss. They may advocate their respected ht specialist but they will also tell you their honest opinion on who is good and who is not. We trust them because they have a favorable reputation and they are open to questions, responses, and articles the community posts.

  3. my dermotologist is the co-founder of the National alopecia Areat Fand is pretty excited about this new ordeal, have a look...

     

     

    http://www.puretechventures.com/content/newsFull.asp?fi...id=277&mainPage=news

     

    May 16, 2007

     

    Follica Developing Breakthrough Discovery to Treat Hair Loss, Wounds and Other Degenerative Skin Disorders

     

    BOSTON--(PR NEWSWIRE)"??? Technology licensed by Follica Inc. from the University of Pennsylvania School of Medicine has been used to generate completely new hair follicles for the first time in normal adult mammals. The paper describing the

    experiment was published in the May 17th issue of the scientific journal Nature.

     

    By studying wound healing on a molecular level, Dr. George Cotsarelis and colleagues discovered that the skin has the ability to revert to a more primitive or "embryonic" state as stem cells migrate to the affected area, thereby achieving a regenerative capacity not previously appreciated to occur in adults.

     

    The researchers were able to control the regenerative response, including the extent of new hair follicle formation, by manipulating genetic pathways during this "embryonic window" when new follicles formed. The new hair follicles functioned normally, cycled through the normal stages of hair growth and exhibited normal architecture, including a full complement of stem cells. Cotsarelis and colleagues showed that the induction of this primitive state triggered corresponding embryonic molecular pathways distinct from those active in corresponding cells in adult skin, opening up new treatment options not previously thought to have therapeutic benefit in normal adult skin.

     

    "The "embryonic window" gives us the opportunity to develop disease treatments that act in entirely novel ways," said Daphne Zohar, PureTech Ventures founding managing partner and Follica CEO. "The clinical translation of this technique involves straightforward, safe dermatological procedures, and we are studying the impact of multiple drugs and drug-like compounds on this regenerative response as we advance in preclinical testing."

     

    "This is an extremely exciting discovery and shows promise for treatment of follicular disorders such as hair loss and unwanted excess hair," noted Dr. Vera Price, co-founder of the National Alopecia Areata Foundation, director of the University of California, San Francisco (UCSF) Hair Research Center and a founding scientific advisory board member of Follica Inc.

     

    "The hair follicle is an elegant structure that plays many different roles for human skin, aside from growing hair," said Dr. Rox Anderson, Professor of Dermatology at Harvard Medical School, Director of the Wellman Center for Photomedicine at Massachusetts General Hospital, and founding chairman of Follica's scientific advisory board. "George Cotsarelis' insights into the biology of hair follicles provide new strategies for preventing and treating a variety of skin and hair disorders."

     

    Follica exclusively licensed the technology from The University of Pennsylvania School of Medicine where it is the basis of an ongoing development program. The paper's lead author, Dr. Cotsarelis, is also a co-founder and scientific advisory board member of Follica

     

    About Follica

    Follica Inc., a privately held medical device company, was co-founded by PureTech Ventures and a group of world renowned experts in hair follicle biology and medicine. In addition to hair loss, Follica has intellectual property and development programs in various skin and follicle related indications. Additional Follica contributors include Dr. Kurt Stenn (Aderans Research, formerly of J & J, Yale) member of Follica's scientific advisory board; Dr. Ron Cape (PureTech partner, founder Cetus, former board member Neutrogena) Follica board member; and Dr. Steve Prouty (former J&J skin biology) Follica director of research. www.follicabio.com

     

    About PureTech Ventures

    PureTech Ventures is a Boston-based venture firm specializing in translating breakthrough research from top tier academic institutions into therapies that will impact human health and quality of life. PureTech 's partners include entrepreneurs and leaders from the top echelon of pharma, biotech, medtech and academia. www.puretechventures.com

  4. my dermotologist is the co-founder of the National alopecia Areat Fand is pretty excited about this new ordeal, have a look...

     

     

    http://www.puretechventures.com/content/newsFull.asp?fi...id=277&mainPage=news

     

    May 16, 2007

     

    Follica Developing Breakthrough Discovery to Treat Hair Loss, Wounds and Other Degenerative Skin Disorders

     

    BOSTON--(PR NEWSWIRE)"??? Technology licensed by Follica Inc. from the University of Pennsylvania School of Medicine has been used to generate completely new hair follicles for the first time in normal adult mammals. The paper describing the

    experiment was published in the May 17th issue of the scientific journal Nature.

     

    By studying wound healing on a molecular level, Dr. George Cotsarelis and colleagues discovered that the skin has the ability to revert to a more primitive or "embryonic" state as stem cells migrate to the affected area, thereby achieving a regenerative capacity not previously appreciated to occur in adults.

     

    The researchers were able to control the regenerative response, including the extent of new hair follicle formation, by manipulating genetic pathways during this "embryonic window" when new follicles formed. The new hair follicles functioned normally, cycled through the normal stages of hair growth and exhibited normal architecture, including a full complement of stem cells. Cotsarelis and colleagues showed that the induction of this primitive state triggered corresponding embryonic molecular pathways distinct from those active in corresponding cells in adult skin, opening up new treatment options not previously thought to have therapeutic benefit in normal adult skin.

     

    "The "embryonic window" gives us the opportunity to develop disease treatments that act in entirely novel ways," said Daphne Zohar, PureTech Ventures founding managing partner and Follica CEO. "The clinical translation of this technique involves straightforward, safe dermatological procedures, and we are studying the impact of multiple drugs and drug-like compounds on this regenerative response as we advance in preclinical testing."

     

    "This is an extremely exciting discovery and shows promise for treatment of follicular disorders such as hair loss and unwanted excess hair," noted Dr. Vera Price, co-founder of the National Alopecia Areata Foundation, director of the University of California, San Francisco (UCSF) Hair Research Center and a founding scientific advisory board member of Follica Inc.

     

    "The hair follicle is an elegant structure that plays many different roles for human skin, aside from growing hair," said Dr. Rox Anderson, Professor of Dermatology at Harvard Medical School, Director of the Wellman Center for Photomedicine at Massachusetts General Hospital, and founding chairman of Follica's scientific advisory board. "George Cotsarelis' insights into the biology of hair follicles provide new strategies for preventing and treating a variety of skin and hair disorders."

     

    Follica exclusively licensed the technology from The University of Pennsylvania School of Medicine where it is the basis of an ongoing development program. The paper's lead author, Dr. Cotsarelis, is also a co-founder and scientific advisory board member of Follica

     

    About Follica

    Follica Inc., a privately held medical device company, was co-founded by PureTech Ventures and a group of world renowned experts in hair follicle biology and medicine. In addition to hair loss, Follica has intellectual property and development programs in various skin and follicle related indications. Additional Follica contributors include Dr. Kurt Stenn (Aderans Research, formerly of J & J, Yale) member of Follica's scientific advisory board; Dr. Ron Cape (PureTech partner, founder Cetus, former board member Neutrogena) Follica board member; and Dr. Steve Prouty (former J&J skin biology) Follica director of research. www.follicabio.com

     

    About PureTech Ventures

    PureTech Ventures is a Boston-based venture firm specializing in translating breakthrough research from top tier academic institutions into therapies that will impact human health and quality of life. PureTech 's partners include entrepreneurs and leaders from the top echelon of pharma, biotech, medtech and academia. www.puretechventures.com

  5. If you were still on propecia I would have suggested that you drink a lot of water. This may decrease the harshness of your hangovers and give your kidneys some relief. as you probably know many people report sexual problems due to propecia, I have heard it was once used to castrate men in high doses so sexual side effects are certainly not un common.

     

    Rogaine does cause shedding at first because it is programmed to kill weak thin hairs and replace them with strong ones. Unfortunately it doesn't stop the main hair loss problem DHT so Rogaine will not be as effective propecia. Stick with it though and look for blond baby hairs sprouting.

×
×
  • Create New...